Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Intangibles (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Intangibles for 5 consecutive years, with $14.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles fell 34.43% year-over-year to $14.9 million, compared with a TTM value of $14.9 million through Sep 2025, down 34.43%, and an annual FY2024 reading of $21.9 million, down 12.59% over the prior year.
  • Intangibles was $14.9 million for Q3 2025 at Barinthus Biotherapeutics, down from $20.4 million in the prior quarter.
  • Across five years, Intangibles topped out at $31.4 million in Q4 2021 and bottomed at $14.9 million in Q3 2025.
  • Average Intangibles over 5 years is $25.2 million, with a median of $25.5 million recorded in 2023.
  • The sharpest move saw Intangibles decreased 10.06% in 2022, then tumbled 34.43% in 2025.
  • Year by year, Intangibles stood at $31.4 million in 2021, then fell by 10.06% to $28.3 million in 2022, then fell by 11.18% to $25.1 million in 2023, then fell by 12.59% to $21.9 million in 2024, then crashed by 32.07% to $14.9 million in 2025.
  • Business Quant data shows Intangibles for BRNS at $14.9 million in Q3 2025, $20.4 million in Q2 2025, and $21.2 million in Q1 2025.